Charlotte P M Heemskerk1,2, Marieke Pereboom1, Karlijn van Stralen3, Florine A Berger4, Patricia M L A van den Bemt4, Aaf F M Kuijper3, Ruud T M van der Hoeven1, Aukje K Mantel-Teeuwisse2, Matthijs L Becker5. 1. Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands. 2. Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteitsweg 99, Utrecht, The Netherlands. 3. Spaarne Gasthuis, Spaarnepoort 1, Hoofddorp, the Netherlands. 4. Department of Hospital Pharmacy, Erasmus University Medical Centre, s-Gravendijkwal 230, Rotterdam, the Netherlands. 5. Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands. mbecker@sahz.nl.
Abstract
PURPOSE: Prolongation of the QTc interval may result in Torsade de Pointes, a ventricular arrhythmia. Numerous risk factors for QTc interval prolongation have been described, including the use of certain drugs. In clinical practice, there is much debate about the management of the risks involved. In this study, we quantified the effect of these risk factors on the length of the QTc interval. METHODS: We analyzed all ECGs that were taken during routine practice between January 2013 and October 2016 in the Spaarne Gasthuis, a general teaching hospital in the Netherlands. We collected laboratory values in the week before the ECG recording and the drugs prescribed. For the identification of risk factors, we used multilevel linear regression analysis to correct for multiple ECG recordings per patient. RESULTS: We included 133,359 ECGs in our study, taken in 40,037 patients. Patients using one QT-prolonging drug had a 11.08 ms (95% CI 10.63-11.52; p < 0.001) longer QTc interval. Patients using two QT-prolonging drugs had a 3.04 ms (95% CI 2.06-4.02; p < 0.001) increase in the QTc interval compared to patients using one QT-prolonging drug. Women had a longer QTc interval compared to men (16.30 ms 95% CI 14.59-18.01; p < 0.001). The QTc interval increased with increasing age, but the difference between men and women diminished. Other independent risk factors that significantly prolonged the QTc interval with at least 10 ms were hypokalemia, hypocalcemia, and the use of loop diuretics. CONCLUSION: We identified and quantified various risk factors for QTc interval prolongation.
PURPOSE: Prolongation of the QTc interval may result in Torsade de Pointes, a ventricular arrhythmia. Numerous risk factors for QTc interval prolongation have been described, including the use of certain drugs. In clinical practice, there is much debate about the management of the risks involved. In this study, we quantified the effect of these risk factors on the length of the QTc interval. METHODS: We analyzed all ECGs that were taken during routine practice between January 2013 and October 2016 in the Spaarne Gasthuis, a general teaching hospital in the Netherlands. We collected laboratory values in the week before the ECG recording and the drugs prescribed. For the identification of risk factors, we used multilevel linear regression analysis to correct for multiple ECG recordings per patient. RESULTS: We included 133,359 ECGs in our study, taken in 40,037 patients. Patients using one QT-prolonging drug had a 11.08 ms (95% CI 10.63-11.52; p < 0.001) longer QTc interval. Patients using two QT-prolonging drugs had a 3.04 ms (95% CI 2.06-4.02; p < 0.001) increase in the QTc interval compared to patients using one QT-prolonging drug. Women had a longer QTc interval compared to men (16.30 ms 95% CI 14.59-18.01; p < 0.001). The QTc interval increased with increasing age, but the difference between men and women diminished. Other independent risk factors that significantly prolonged the QTc interval with at least 10 ms were hypokalemia, hypocalcemia, and the use of loop diuretics. CONCLUSION: We identified and quantified various risk factors for QTc interval prolongation.
Entities:
Keywords:
Drug-related side effects and adverse reactions; Electrocardiography; Hospital information systems; Long QT syndrome/chemically induced; Risk assessment
Authors: Andreas D Meid; Anna von Medem; Dirk Heider; Jürgen-Bernhard Adler; Christian Günster; Hanna M Seidling; Renate Quinzler; Hans-Helmut König; Walter E Haefeli Journal: Drug Saf Date: 2017-02 Impact factor: 5.606
Authors: David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin Journal: Medicine (Baltimore) Date: 2003-07 Impact factor: 1.889
Authors: Steven Stettner; Sarah Adie; Sarah Hanigan; Michael Thomas; Kristen Pogue; Christopher Zimmerman Journal: Appl Clin Inform Date: 2022-01-05 Impact factor: 2.342
Authors: Louise Christensen; J Rick Turner; Gregory M Peterson; Mark Naunton; Jackson Thomas; Kwang Choon Yee; Sam Kosari Journal: J Clin Med Date: 2019-11-04 Impact factor: 4.241
Authors: Javad Alizargar; Nan-Chen Hsieh; Shu-Fang Vivienne Wu; Shih-Yen Weng Journal: Int J Environ Res Public Health Date: 2020-01-10 Impact factor: 3.390
Authors: Matthijs L Becker; Dominic Snijders; Claudia W van Gemeren; Hylke Jan Kingma; Steven F L van Lelyveld; Thijs J Giezen Journal: Cardiovasc Toxicol Date: 2021-01-02 Impact factor: 2.755